Replies to post #118569 on Biotech Values

[DewDiligence]

NVS has long had a more deliberate style of M&A than most Big Pharma. Exhibit A is the drawn-out pursuit of Chiron, and Exhibits B and C are the Alcon and Speedel deals, where the former was completed in three steps and the latter involved an out-license and clawback along the way.

On the other hand, the Sandoz division of NVS has used a quick-strike approach in its deals for Hexal and Eon, so there’s a disparity in style within the same corporate umbrella. Moreover, MNTA is a singular case insofar as it has expertise that could help both Sandoz and NVS’ pharma division, which makes handicapping a possible deal more difficult.

The bottom line is that I wouldn’t presume NVS is going to make a move to acquire MNTA during the next couple of years.

[DewDiligence]

Alcon Digested, NVS Is Back in Hunt for Acquisitions

[This is somewhat bullish, but it doesn’t cause me to change the opinion in #msg-62283456 unduly.]

http://www.reuters.com/article/2011/07/11/novartis-idUSLDE76A10C20110711

›Mon Jul 11, 2011 8:36am EDT

ZURICH, July 11 (Reuters) - Swiss drugmaker Novartis AG could soon be in the position to go for deals again after its $51 billion buy of U.S.-listed eyecare group Alcon, the group's chief executive was quoted as saying on Monday.

CEO Joe Jimenez said paying down Novartis' debt of $22 billion was the group's first priority but that it should be able to do this quickly thanks to its strong cash flow.

"We could soon be in the position to go for acquisitions again, even if they are not as big as Alcon," Jimenez said in an interview with Swiss newspaper Aargauer Zeitung.

Jimenez also said Novartis was sticking to its target to grow group sales around the double-digit mark this year, and that the drugmaker was on track to further increase its core operating income margin in constant currencies.

Novartis is due to publish its half-year results on July 19.‹